Uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin
Calcium channel blockers: verapamil, diltiazem
Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
Contraindications to the use of beta-blockers, like, uncontrolled depression, unstable angina pectoris, uncontrolled heart failure (grade III or IV), hypotension (systolic blood pressure <  mmHg), severe asthma or chronic obstructive pulmonary disease (COPD), uncontrolled type I or type II diabetes mellitus (glycosylated hemoglobin [HbAC] > . or fasting plasma glucose >  mg/dl at screening), symptomatic peripheral arterial disease or Raynauds syndrome, untreated pheochromocytoma, current use or past use in the last two years of beta-blockers or calcium channel blockers
Clinically significant cardiac arrhythmias including bradyarrhythmias and/or subjects who require anti-arrhythmic therapy (excluding beta blockers or digoxin). Subjects with controlled atrial fibrillation are not excluded.
Inability to suspend treatment with anti-hypertensive medication (including but not limited to: diuretics, beta-blockers, angiotensin converting enzyme [ACE] inhibitors, aldosterone antagonists, etc) for  hours pre and post each Pexa-Vec administration
Patients requiring treatment with one or more beta-blockers (metoprolol, atenolol, propranolol) or calcium channel blockers with atrioventricular (AV)-nodal blocking activity (verapamil, diltiazem); patients being treated with AV nodal blocker (beta-blocker or calcium channel blocker) are allowed if the agent is being used only for correcting hypertension, and if an acceptable alternative is available (for example, transitioning from a drug such as atenolol to Lisinopril or amlodipine) prior to starting treatment on therapy
Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
Patients currently on beta blockers
Patients on chronic nitrate therapy or alpha-blockers
Anti-arrhythmia medication other than beta-blockers or digoxin
New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea, orthopnea, or edema that requires current treatment with angiotensin convering enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, or diuretics
Anti-arrhythmic therapy other than beta blockers or digoxin
Concomitant use of these drugs at baseline and for the duration of digoxin administration (if randomized to receive it):\r\n* The calcium channel blockers diltiazem or verapamil\r\n* Cardiac arrhythmic agents (such as quinidine, amiodarone)\r\n* Other cytochrome P (P) inducer/inhibitors\r\n* NOTE: patients already receiving digoxin are also excluded; patients who take calcium carbonate antacids (e.g., Maalox, Tums, Rolaids) or antidiarrheal adsorbents (kaolin and pectin) should avoid taking these at the same time as the digoxin dose
Unstable angina, symptomatic congestive heart failure or cardiac arrhythmia requiring anti-arrhythmic therapy (beta-blockers, calcium channel blockers and digoxin are allowed)
Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin.
Patients with third degree or complete heart block are not eligible unless a pacemaker is in place; patients on medications, which alter cardiac conduction, such as digitalis, beta-blockers, or calcium channel blockers, or who have other conduction abnormalities or cardiac dysfunction could be entered at the discretion of the investigators
Cardiac arrhythmias requiring anti-arrhythmic therapy; Note: pace makers, beta blockers, or digoxin are permitted
Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
Clinically significant cardiac arrhythmias and/or patients who require anti-arrhythmic therapy (excluding beta blockers or digoxin); patients with controlled atrial fibrillation are not excluded
On beta-blocker treatment; if discontinued, patients must have been off beta-blockers for at least  months
Normotensive individuals not already on beta blockers (may be on other anti hypertensives): SBP =< , DBP =< 
Any patients already on beta-blockers or contraindicated to receive beta-blockers
Hypersensitivity to propranolol, or beta-blockers
Clinically significant cardiac arrhythmias including bradyarrhythmias and/or subjects who require anti-arrhythmic therapy (excluding beta blockers or digoxin). Subjects with controlled atrial fibrillation are not excluded
History of documented congestive heart failure (CHF), New York Heart Association class II/III/IV, with a history of dyspnea, orthopnea or edema that requires current treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers or diuretics; NOTE: use of these medications for the treatment of hypertension is allowed
Have cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin.
Patients on beta blockers
Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin
Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
History of documented congestive heart failure (CHF), New York Heart Association class II/III/IV, with a history of dyspnea, orthopnea or edema that requires current treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers or diuretics; NOTE: use of these medications for the treatment of hypertension is allowed
Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin.
Patients with other established indications for ivabradine: stable, symptomatic chronic heart failure (HF) with a left ventricular ejection fraction ? % and in sinus rhythm with a resting heart rate (HR) ?  bpm, who are taking maximally tolerated doses of beta-blockers or have contraindications to beta-blocker use
History of drug sensitivity or allergic reaction to alpha- or beta-blockers
Use of an investigational drug or beta adrenergic blockers, including metoprolol, sotalol, within  days of randomization
Patient requires regular use of beta blockers or calcium channel blockers
No use of any anti-arrhythmic medication (except for beta-blockers and calcium channel blockers) including intravenous lidocaine, linezolid, ipratropium, or medications with anti-cholinergic potency (including neostigmine, a tricyclic antidepressant or a monoamine oxidase inhibitor) within  weeks prior to registration
Current treatment with angiotensin converting enzyme (ACE)-inhibitors or beta blockers
Allergies or inability to tolerate beta blockers previously due to bradycardia, hypotension, or atrioventricular (AV) block
No other concurrent angiotensin-converting enzyme (ACE) inhibitors, ?-blockers, or digoxin
Current use of () medications/supplements to control blood pressure (e.g. beta-blockers, nitrates, calcium channel blockers, phosphodiesterase- [PGE] inhibitors) or () the use of statins for cholesterol;
Use of an investigational drug or beta adrenergic blockers, including metoprolol, sotalol, within  days of enrollment
History of drug sensitivity or allergic reaction to alpha or beta-blockers
Use of any other blood pressure lowering medication for treatment of hypertension within  days of enrollment except calcium channel blockers and diuretics
Taking medication that may impair PA tolerance or performance (e.g., beta blockers)
Use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, aldosterone, renin blockers, aspirin, statins, sildenafil (or other PDE inhibitors) and non-steroidal antiinflammatory drugs (NSAIDs)